Paul Herzich - Dec 2, 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Chief Technology Officer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Stock symbol
SLDB
Transactions as of
Dec 2, 2024
Transactions value $
-$15,551
Form type
4
Date filed
12/4/2024, 04:42 PM
Previous filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +7.24K +93.77% 15K Dec 2, 2024 Direct F1, F2
transaction SLDB Common Stock Sale -$15.6K -2.78K -18.56% $5.60 12.2K Dec 3, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -7.24K -33.33% $0.00 14.5K Dec 2, 2024 Common Stock 7.24K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2 Includes 1,698 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024.
F3 This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Dr. Herzich.
F4 The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.